Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors
摘要:
A successful structure-based design of a class of non-peptide small-molecule MDM2 inhibitors targeting the p53-MDM2 protein-protein interaction is reported. The most potent compound 1d binds to MDM2 protein with a Ki value of 86 nM and is 18 times more potent than a natural p53 peptide (residues 16-27). Compound 1d is potent in inhibition of cell growth in LNCaP prostate cancer cells with wild-type p53 and shows only a weak activity in PC-3 prostate cancer cells with a deleted p53. Importantly, 1d has a minimal toxicity to normal prostate epithelial cells. Our studies provide a convincing example that structure-based strategy can be employed to design highly potent, non-peptide, cell-permeable, small-molecule inhibitors to target protein-protein interaction, which remains a very challenging area in chemical biology and drug design.
There are provided compounds of the formula
and pharmaceutically acceptable salts and esters thereof
wherein W, V, X, Y, A, R and R′ are as described herein.
The compounds are useful as anticancer agents.
A compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity is provided. The present invention provides a dispiropyrrolidine derivative represented by the following formula (1), which has various substituents, inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity, wherein R
1
, R
2
, R
3
, ring A, and ring B in formula (1) respectively have the same meanings as defined in the specification.
The present invention relates to spiroindolinone derivatives of the formula
and enantiomers and pharmaceutically acceptable salts and esters thereof which have utility as antiproliferative agents, especially, as anticancer agents.
There are provided compounds of the general formulas
wherein X, Y, R
1
, R
2
, R
3
and R
4
are as described herein. The compounds exhibit anticancer activity.
There are provided compounds of the general formulas
wherein X, Y, R
1
, R
2
, R
3
, R
4
and R
5
are as described herein. The compounds exhibit anticancer activity.